Nutrition Research Journal Study Reports EpiCor's Immunomodulating Effects

CEDAR RAPIDS, Iowa, July 30, 2007 - EpiCor (R), the immune balancing all-natural, high-metabolite immunogen manufactured by Embria (R) Health Sciences, is the subject of a recently published Nutrition Research Journal in vitro study that evaluated the consumable ingredient’s immunomodulating effects on human leukocytes. The Journal's June 2007 issue reports that EpiCor possesses significant anti-inflammatory activity and induces direct activation and increased chemotactic awareness of lymphocyte subsets.

The study's lead researchers selected anti-inflammatory and lymphocyte activation assays because of EpiCor's high oxygen radical absorbance capacity value, as well as the initial evidence pointing to EpiCor's favorable immunomodulating effects on factory employees manufacturing the ingredient. The company's overall health care costs were recorded as half the cost of insuring comparable Blue Cross Blue Shield groups.

In this study, researchers found that EpiCor:
-- Reduced production of the pro-inflammation reactive oxygen species (ROS);
-- Activated antibody-generating B lymphocytes;
-- Increased the activity of Natural Killer (NK) cells, making them more efficient; and
-- Inhibited mitogen-induced T-cell proliferation and reduced production of the pro-inflammatory cytokine interferon gamma.

"The favorable results of this study prove EpiCor's effectiveness in keeping vital immune system components balanced and in-check," said Larry Robinson, PhD, vice president of scientific affairs, Embria Health Sciences. "It also opens the door to further research surrounding EpiCor's impact on human antiviral defense mechanisms and antibody production."

About EpiCor:
EpiCor is an all-natural, high-metabolite immunogen designed to modulate and balance the human immune system. This dried, complex fermentation product is derived from a proprietary process consisting of Saccharomyces cerevisiae and the medium in which it is grown.
EpiCor received self-affirmed GRAS status in May 2006 from an expert panel comprised of members with extensive Food and Drug Administration (FDA), Environmental Protection Agency (EPA) and National Institute of Health (NIH) experience. Clinical research on EpiCor has been presented at the Federation of American Societies for Experimental Biology (FASEB) Conference and the American College of Nutrition (ACN) Symposium.

For more information on EpiCor, visit For an abstract of this study, please contact Amanda Holty at 801.538.0777 or [email protected].

# # #

Jensen, G, et al. An antiinflammatory immunogen from yeast culture induces activation and alters chemokine receptor expression on human natural killer cells and B lymphocytes in vitro. Nutrition Research (2007), 27:6, 327-335.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.